BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma

Elena Porcù, Francesca Maule, Daniele Boso, Elena Rampazzo, Vito Barbieri, Gaia Zuccolotto, Antonio Rosato, Chiara Frasson, Giampietro Viola, Alessandro Della Puppa, Giuseppe Basso, Luca Persano

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is a highly vascularized and aggressive brain tumor, with a strong ability to disseminate and invade the surrounding parenchyma. In addition, a subpopulation of GBM stem cells has been reported to possess the ability to transdifferentiate into tumor-derived endothelial cells (TDECs), supporting the resistance to anti-angiogenic treatments of newly formed blood vessels. Bone Morphogenetic Protein 9 (BMP9) is critically involved in the processes of cancer cell differentiation, invasion and metastasis, representing a potential tool in order to impair the intrinsic GBM aggressiveness. Here we demonstrate that BMP9 is able to trigger the activation of SMADs in patient-derived GBM cells, and to strongly inhibit proliferation and invasion by reducing the activation of PI3K/AKT/MAPK and RhoA/Cofilin pathways, respectively. Intriguingly, BMP9 treatment is sufficient to induce a strong differentiation of GBM stem-like cells and to significantly counteract the already reported process of GBM cell transdifferentiation into TDECs not only in in vitro mimicked TDEC models, but also in vivo in orthotopic xenografts in mice. Additionally, we describe a strong BMP9-mediated inhibition of the whole angiogenic process engaged during GBM tumor formation. Based on these results, we believe that BMP9, by acting at multiple levels against GBM cell aggressiveness, can be considered a promising candidate, to be further developed, for the future therapeutic management of GBM.

Original languageEnglish
Pages (from-to)1808-1822
Number of pages15
JournalCell Death and Differentiation
Volume25
Issue number10
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Growth Differentiation Factor 2
Glioblastoma
Endothelial Cells
Neoplasms
Stem Cells
Cell Transdifferentiation
Actin Depolymerizing Factors
Phosphatidylinositol 3-Kinases
Heterografts
Brain Neoplasms
Blood Vessels
Cell Differentiation
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Porcù, E., Maule, F., Boso, D., Rampazzo, E., Barbieri, V., Zuccolotto, G., ... Persano, L. (2018). BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. Cell Death and Differentiation, 25(10), 1808-1822. https://doi.org/10.1038/s41418-018-0149-9

BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. / Porcù, Elena; Maule, Francesca; Boso, Daniele; Rampazzo, Elena; Barbieri, Vito; Zuccolotto, Gaia; Rosato, Antonio; Frasson, Chiara; Viola, Giampietro; Della Puppa, Alessandro; Basso, Giuseppe; Persano, Luca.

In: Cell Death and Differentiation, Vol. 25, No. 10, 01.11.2018, p. 1808-1822.

Research output: Contribution to journalArticle

Porcù, E, Maule, F, Boso, D, Rampazzo, E, Barbieri, V, Zuccolotto, G, Rosato, A, Frasson, C, Viola, G, Della Puppa, A, Basso, G & Persano, L 2018, 'BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma', Cell Death and Differentiation, vol. 25, no. 10, pp. 1808-1822. https://doi.org/10.1038/s41418-018-0149-9
Porcù, Elena ; Maule, Francesca ; Boso, Daniele ; Rampazzo, Elena ; Barbieri, Vito ; Zuccolotto, Gaia ; Rosato, Antonio ; Frasson, Chiara ; Viola, Giampietro ; Della Puppa, Alessandro ; Basso, Giuseppe ; Persano, Luca. / BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma. In: Cell Death and Differentiation. 2018 ; Vol. 25, No. 10. pp. 1808-1822.
@article{462080546d284d3fa096b1e90c399639,
title = "BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma",
abstract = "Glioblastoma multiforme (GBM) is a highly vascularized and aggressive brain tumor, with a strong ability to disseminate and invade the surrounding parenchyma. In addition, a subpopulation of GBM stem cells has been reported to possess the ability to transdifferentiate into tumor-derived endothelial cells (TDECs), supporting the resistance to anti-angiogenic treatments of newly formed blood vessels. Bone Morphogenetic Protein 9 (BMP9) is critically involved in the processes of cancer cell differentiation, invasion and metastasis, representing a potential tool in order to impair the intrinsic GBM aggressiveness. Here we demonstrate that BMP9 is able to trigger the activation of SMADs in patient-derived GBM cells, and to strongly inhibit proliferation and invasion by reducing the activation of PI3K/AKT/MAPK and RhoA/Cofilin pathways, respectively. Intriguingly, BMP9 treatment is sufficient to induce a strong differentiation of GBM stem-like cells and to significantly counteract the already reported process of GBM cell transdifferentiation into TDECs not only in in vitro mimicked TDEC models, but also in vivo in orthotopic xenografts in mice. Additionally, we describe a strong BMP9-mediated inhibition of the whole angiogenic process engaged during GBM tumor formation. Based on these results, we believe that BMP9, by acting at multiple levels against GBM cell aggressiveness, can be considered a promising candidate, to be further developed, for the future therapeutic management of GBM.",
author = "Elena Porc{\`u} and Francesca Maule and Daniele Boso and Elena Rampazzo and Vito Barbieri and Gaia Zuccolotto and Antonio Rosato and Chiara Frasson and Giampietro Viola and {Della Puppa}, Alessandro and Giuseppe Basso and Luca Persano",
year = "2018",
month = "11",
day = "1",
doi = "10.1038/s41418-018-0149-9",
language = "English",
volume = "25",
pages = "1808--1822",
journal = "Cell Death and Differentiation",
issn = "1350-9047",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - BMP9 counteracts the tumorigenic and pro-angiogenic potential of glioblastoma

AU - Porcù, Elena

AU - Maule, Francesca

AU - Boso, Daniele

AU - Rampazzo, Elena

AU - Barbieri, Vito

AU - Zuccolotto, Gaia

AU - Rosato, Antonio

AU - Frasson, Chiara

AU - Viola, Giampietro

AU - Della Puppa, Alessandro

AU - Basso, Giuseppe

AU - Persano, Luca

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Glioblastoma multiforme (GBM) is a highly vascularized and aggressive brain tumor, with a strong ability to disseminate and invade the surrounding parenchyma. In addition, a subpopulation of GBM stem cells has been reported to possess the ability to transdifferentiate into tumor-derived endothelial cells (TDECs), supporting the resistance to anti-angiogenic treatments of newly formed blood vessels. Bone Morphogenetic Protein 9 (BMP9) is critically involved in the processes of cancer cell differentiation, invasion and metastasis, representing a potential tool in order to impair the intrinsic GBM aggressiveness. Here we demonstrate that BMP9 is able to trigger the activation of SMADs in patient-derived GBM cells, and to strongly inhibit proliferation and invasion by reducing the activation of PI3K/AKT/MAPK and RhoA/Cofilin pathways, respectively. Intriguingly, BMP9 treatment is sufficient to induce a strong differentiation of GBM stem-like cells and to significantly counteract the already reported process of GBM cell transdifferentiation into TDECs not only in in vitro mimicked TDEC models, but also in vivo in orthotopic xenografts in mice. Additionally, we describe a strong BMP9-mediated inhibition of the whole angiogenic process engaged during GBM tumor formation. Based on these results, we believe that BMP9, by acting at multiple levels against GBM cell aggressiveness, can be considered a promising candidate, to be further developed, for the future therapeutic management of GBM.

AB - Glioblastoma multiforme (GBM) is a highly vascularized and aggressive brain tumor, with a strong ability to disseminate and invade the surrounding parenchyma. In addition, a subpopulation of GBM stem cells has been reported to possess the ability to transdifferentiate into tumor-derived endothelial cells (TDECs), supporting the resistance to anti-angiogenic treatments of newly formed blood vessels. Bone Morphogenetic Protein 9 (BMP9) is critically involved in the processes of cancer cell differentiation, invasion and metastasis, representing a potential tool in order to impair the intrinsic GBM aggressiveness. Here we demonstrate that BMP9 is able to trigger the activation of SMADs in patient-derived GBM cells, and to strongly inhibit proliferation and invasion by reducing the activation of PI3K/AKT/MAPK and RhoA/Cofilin pathways, respectively. Intriguingly, BMP9 treatment is sufficient to induce a strong differentiation of GBM stem-like cells and to significantly counteract the already reported process of GBM cell transdifferentiation into TDECs not only in in vitro mimicked TDEC models, but also in vivo in orthotopic xenografts in mice. Additionally, we describe a strong BMP9-mediated inhibition of the whole angiogenic process engaged during GBM tumor formation. Based on these results, we believe that BMP9, by acting at multiple levels against GBM cell aggressiveness, can be considered a promising candidate, to be further developed, for the future therapeutic management of GBM.

UR - http://www.scopus.com/inward/record.url?scp=85049601409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049601409&partnerID=8YFLogxK

U2 - 10.1038/s41418-018-0149-9

DO - 10.1038/s41418-018-0149-9

M3 - Article

C2 - 29977042

AN - SCOPUS:85049601409

VL - 25

SP - 1808

EP - 1822

JO - Cell Death and Differentiation

JF - Cell Death and Differentiation

SN - 1350-9047

IS - 10

ER -